期刊文献+

梯度洗脱HPLC测定奥达特罗的有关物质 被引量:1

Detection of related substances of olodaterol by HPLC with gradient elution
原文传递
导出
摘要 目的:建立奥达特罗有关物质检查的方法。方法:采用Sapphire C18色谱柱(250 mm×4.6 mm,5μm);以10 mmol·L-1磷酸二氢钠溶液为流动相A、乙腈为流动相B进行梯度洗脱;流速为1 m L·min-1;检测波长为220 nm;柱温30℃。结果:主成分与5种有关物质分离完全。奥达特罗的线性范围为0.01~25μg·mL^(-1),相关系数r为1.000 0,检测限为4.06 ng·mL^(-1)。各杂质的线性范围为0.04~5μg·mL^(-1),相关系数r≥0.999 9,精密度良好。奥达特罗1%自身对照溶液重复进样的RSD值为0.35%。各已知杂质以杂质对照品法,未知杂质以主成分自身对照法计算杂质含量,3批样品最大单个杂质不超过0.3%,总杂质含量不超过0.7%。结论:该方法简便、灵敏、准确、专属性强,可用于奥达特罗有关物质的检查。 Objective: To establish an HPLC method for the detection of related substances of olodaterol.Methods: The separation was performed on Sapphire C18 column( 250 mm × 4. 6 mm,5 μm). Gradient elution was used to determine the related substances of olodaterol with 10 mmol·L-1 sodium dihydrogen phosphate as mobile phase A and acetonitrile as mobile phase B. The flow rate was 1 m L·min-1. The detection wavelength was220 nm,and the column temperature was 30 ℃. The contents of known impurities was determined by external standard method and that of the unknown impurities were calculated by main component self-comparison method.Results: The related substances were completely separated from the principal component. The linear range of olodaterol was 0. 01 - 25 μg·m L^-1,with correlation coefficient of 1. 000 0 and limit of detection of 4. 06 ng·m L^-1.The linear ranges of the impurities were 0. 04 - 5 μg·m L-1( r≥0. 999 9). The precision was good,with RSD of0. 35% for duplicate injection of 1% olodaterol solution. The content of individual impurity was lower than 0. 3%,and that of total impurities was lower than 0. 7%. Conclusion: The method is simple,sensitive,accurate and specific,and can be used to determine the related substances of olodaterol.
出处 《中国新药杂志》 CAS CSCD 北大核心 2018年第4期483-488,共6页 Chinese Journal of New Drugs
关键词 奥达特罗 有关物质 高效液相色谱 olodaterol related substance HPLC
  • 相关文献

参考文献5

二级参考文献35

  • 1Rabe K F, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary [J]. Am J Respir Crit Care Med, 2007, 176(6): 532-555.
  • 2Pauwels R A, Rabe K F. Burden and clinical features of chronic obstructive pulmonary disease (COPD) [J]. Lancet, 2004, 364(9434): 613-620.
  • 3World Health Organization. Global alliance against chronic respiratory diseases [EB/OL]. [2011-08-18]. http://www.who.int/mediacentre/factsheets/fs315/en/index. html.
  • 4World Health Organization. World health report 2004 statistical annex: annex table 2 and 3:120-131. [EB/OL]. [2013-02-18]. http://www.who.int/whr/2004/annex/en/.
  • 5Ulrik C S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study [J]. Thorax, 1995, 50: 750-754.
  • 6Boyd G, Morice A H, Pounsford J C, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) [J]. EurRespirJ, 1997, 10(4): 815-821.
  • 7Cazzola M, Matera M C: Santangelo C: et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study [J]. Respir Med, 1995, 89(5): 357-362.
  • 8Rossi A, Kristufek P, Levine B E, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment ofCOPD [J]. Chest, 2002, 121(4): 1058-1069.
  • 9Tamura : Ohm K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch [J]. RespirMed, 2007, 101(9): 1895-1902.
  • 10Hochrainer D, H6lz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers [J]. J Aerosol Med, 2005, 18(3): 273-282.

共引文献14

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部